Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma

By Donskov Frede   Bennedsgaard Karen   Hokland Marianne   Marcussen Niels   Fisker Rune   Madsen Hans   Fode Kirsten   Maase Hans  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 8, 2004-08 ,pp. : 729-739

Springer Publishing Company

Access to resources Recommend Favorite

Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study

By Olivier Rixe   Jean-baptiste Meric   David Khayat   Claude Soubrane   Roger Mouawad  

Cytokines, Cellular & Molecular Therapy, Vol. 7, Iss. 4, 2002-12 ,pp. : 151-156

Informa Healthcare

Access to resources Recommend Favorite

Home Therapy with Autologous Tumour-infiltrating Lymphocytes and Subcutaneous Interleukin-2 in Metastatic Melanoma

By Tessier M.-H.   Pandolfino M.-C.   Jotereau F.   Boudart D.   Litoux P.   Dreno B.  

European Journal of Cancer, Vol. 32, Iss. 4, 1996-04 ,pp. : 735-736

Elsevier

Access to resources Recommend Favorite

Stem cell factor affects tumour progression markers in metastatic melanoma cells

By Prignano Francesca   Gerlini Gianni   Salvatori Benedetta   Orlando Claudio   Mazzoli Sandra   Pimpinelli Nicola   Moretti Silvia  

Clinical and Experimental Metastasis, Vol. 23, Iss. 3-4, 2006-06 ,pp. : 177-186

Springer Publishing Company

Access to resources Recommend Favorite

Acute Effects of Pamidronate Administration on Serum Levels of Interleukin-6 in Advanced Solid Tumour Patients with Bone Metastases and their Possible Implications in the Immunotherapy of Cancer with Interleukin-2

By Lissoni P.   Cazzaniga M.   Barni S.   Perego M.S.   Brivio F.   Fumagalli L.   Tancini G.  

European Journal of Cancer, Vol. 33, Iss. 2, 1997-02 ,pp. : 304-306

Elsevier

Access to resources Recommend Favorite